2016
DOI: 10.1016/s1470-2045(16)30392-8
|View full text |Cite
|
Sign up to set email alerts
|

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

6
327
0
2

Year Published

2017
2017
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 312 publications
(335 citation statements)
references
References 24 publications
6
327
0
2
Order By: Relevance
“…Brigatinib recently received accelerated FDA approval for use in advanced ALK -rearranged NSCLC (78, 79). Like crizotinib and ceritinib, it also has anti-ROS1 activity based on preclinical studies, with an IC 50 of 7.5 nM (versus anti-ALK IC 50 of 9.8 nM) in CD74-ROS1 -expressing Ba/F3 cells (80).…”
Section: Ros1-targeted Therapies In Lung Cancermentioning
confidence: 99%
“…Brigatinib recently received accelerated FDA approval for use in advanced ALK -rearranged NSCLC (78, 79). Like crizotinib and ceritinib, it also has anti-ROS1 activity based on preclinical studies, with an IC 50 of 7.5 nM (versus anti-ALK IC 50 of 9.8 nM) in CD74-ROS1 -expressing Ba/F3 cells (80).…”
Section: Ros1-targeted Therapies In Lung Cancermentioning
confidence: 99%
“…The phase I/II trial showed an ORR of 72% in previously crizotinib-treated ALK -rearranged NSCLC patients with an intracranial response rate of 53% [33]. Updated data presented at the 2016 World Conference on Lung Cancer (WCLC) showed a mPFS of 13.4 months in crizotinib-refractory patients, which is longer than for ceritinib and alectinib in this setting [34].…”
Section: Therapeutic Optionsmentioning
confidence: 99%
“…Updated data presented at the 2016 World Conference on Lung Cancer (WCLC) showed a mPFS of 13.4 months in crizotinib-refractory patients, which is longer than for ceritinib and alectinib in this setting [34]. An AE unique to brigatinib is early pulmonary events, including cough, dyspnea, pneumonia/pneumonitis, and hypoxia, which occurred in 6–8% of patients [33, 35] with onset typically within 7 days after initiation of brigatinib therapy. The phase II ALTA trial therefore looked at two different dosing schedules at either 90 mg daily (group A) or 90 mg daily with escalation to 180 mg daily after 7 days (group B).…”
Section: Therapeutic Optionsmentioning
confidence: 99%
“…Further clinical trials will help address outstanding questions. As more data become available on additional ALK-inhibitors such as brigatinib and lorlatinib, the question will be of the optimal sequencing of therapies, especially since early reports demonstrate CNS activity with these agents as well (21). Also, the choice of SRS, alectinib, or both has yet to be delineated in prospective trials.…”
Section: Commentarymentioning
confidence: 99%